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•   Aging  is the main risk factor  of most chronic diseases found at old age. 
•   Senescent cells (SC) accumulate through lifetime causing tissue dysfunction,  
and their elimination could alleviate their damaging features without affecting 
their short-term beneficial effects: 
•   Revising  the  interconnectedness of cellular senescence and aging. 
•   Gathering all data available on Dasatinib + Quercetin (D+Q) . 
•   Reviewing  the potential of senolytic substances to improve age-related 
diseases as a whole. 
•  Thorough review of articles covering the effect of  D+Q on age-related diseases. 
•  Sources: Pubmed (MEDLINE), Web of Science, cross-referencing. 
•  Key words: aging, senescence, senolytic, age-related,  D+Q.  
Figure. 1. SC clearance has beneficial effects by killing long-lived SC. ▲ 
Figure 2. The INK-ATTAC mouse allows selective p16+-SC ablation upon drug treatment (1). ▲ 
Figure. 7. Both A and tau pathology (AD) models benefit from D+Q. ▲ 
Figure. 9. SC induce fatty liver disease and their selective ablation with 
D+Q improves hepatic steatosis. ▲ 
Figure. 10. Completed & ongoing CT on 
age-related diseases. ▲ 
Figure. 8. Many aspects of type II diabetes are eased with D+Q. ▲ 
       D+Q alleviates physical dysfunction          D+Q relieves Alzheimer’s Disease 
Figure. 5. Summary of D+Q’s  
effects on the vasculature and the heart. ▲ Figure. 4. D+Q improves overall bone health in old mice. ▲ 
Figure. 6. Natural/SC-induced frailty  
and longevity improve after D+Q (3). ▲ 
•   Senescent cells causally contribute to tissue dysfunction and are considered one 
of the main contributors of aging. 
•   The senolytic treatment D+Q, discovered in 2015, ameliorates an extensive list of 
age-related diseases and phenotypes solely by eliminating senescent cells. 
•   Polypharmacy is especially prevalent in the elderly, so, in this scenario, D+Q are 
candidates to tackle age-related pathologies as a whole at once. 
•   As phase I–II clinical trials follow, newer, more selective senolytics are required for 
targeting especifically different SC populations. 
1. Baker D, Wijshake T, Tchkonia T, LeBrasseur N, Childs B, van de Sluis B, et al. Clearance of p16Ink4a positive senescent cells delays ageing associated disorders. Nature. 2011;479(7372):232-236. 
2. Zhu Y, Tchkonia T, Pirtskhalava T, Gower A, Ding H, Giorgadze N, et al. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell. 2015;14(4):644-658.  
3. Xu M, Pirtskhalava T, Farr J, Weigand B, Palmer A, Weivoda M, et al. Senolytics improve physical function and increase lifespan in old age. Nature Medicine. 2018;24(8):1246-1256. 
 Khosla S, Farr J, Tchkonia T, Kirkland J. The role of cellular senescence in ageing and endocrine disease. Nature Reviews Endocrinology. 2020;16(5):263-275.  
 
 
SENESCENT CELL 
•   Senolytic substances kill SC specifically. 
•   They target prosurvival networks. 
•   Molecular actions not wholly elucidated. 
 
 
  Dasatinib (D) is a pan-tyrosine kinase inhibitor. 
  Quercetin (Q) inhibits PI3K. 
 
Figure 3. Proposed molecular pathway of D and Q (2). ▶ 
